Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2A | Q12879 | 4/20 | 0.77 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.77 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16598210 | 0.90 | GRIN2A (0.74) | GRIN2AGRIN1GRIN2BKMT2ASCD | |
| SCHEMBL16598233 | 0.90 | GRIN2A (0.85) | GRIN2AGRIN1GRIN2BKMT2ACASP3 | |
| SCHEMBL16598056 | 0.87 | GRIN2A (0.87) | GRIN2AGRIN1GRIN2BKMT2ASCD | |
| SCHEMBL16598054 | 0.87 | GRIN2A (1.00) | GRIN2AGRIN1GRIN2BKMT2ACASP3 | |
| SCHEMBL16598092 | 0.86 | GRIN2A (0.61) | GRIN2AGRIN1GRIN2BKMT2ASCD | |
| SCHEMBL16598003 | 0.86 | GRIN2A (0.85) | GRIN2AGRIN1GRIN2BKMT2ACASP3 | |
| SCHEMBL16615940 | 0.85 | GRIN2A (0.68) | GRIN2AGRIN1GRIN2BKMT2ACASP3 | |
| SCHEMBL16615960 | 0.85 | GRIN2A (0.82) | GRIN2AGRIN1GRIN2BKMT2ASCD | |
| SCHEMBL16598319 | 0.85 | GRIN2A (0.69) | GRIN2AGRIN1GRIN2BKMT2ASCD | |
| SCHEMBL16598350 | 0.84 | GRIN2A (0.77) | GRIN2AGRIN1GRIN2BKMT2ASCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963434-B2 | N-arylmethyl sulfonamide negative modulators of NR2A | LUC THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9963434-B2 | N-arylmethyl sulfonamide negative modulators of NR2A | LUC THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20160311782-A1 | N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A | NOVARTIS AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-20160311782-A1 | N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A | NOVARTIS AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-20150141433-A1 | N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A | MNEMOSYNE PHARMACEUTICALS, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20150141433-A1 | N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A | MNEMOSYNE PHARMACEUTICALS, INC. | 2015-05-21 | — | — | US | disclosed |
| WO-2015048503-A2 | N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A | MNEMOSYNE PHARMACEUTICALS, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311782-A1 | N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A | GRIN2A, GRIN2B, NR2C2 | GRIN2A 1/4885GRIN1 5/4885GRIN2B 2/4885 |
| US-20150141433-A1 | N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A | GRIN2A, GRIN2B, NR2C2 | GRIN2A 1/4885GRIN1 5/4885GRIN2B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.